Site Neutrality Is No Longer a Theory. Here’s What It Means for Your ASC.

For years, site neutrality has been the policy concept that ASC leaders tracked from a safe distance — a potential disruption somewhere on the horizon that hadn’t quite materialized into real financial impact. That changed on November 21, 2025, when CMS released the CY 2026 Hospital Outpatient Prospective Payment System Final Rule. Site neutrality is no longer theoretical. It is showing up in reimbursement data, and 2026 is the year its implications for independent and physician-owned ASCs become concrete.

Understanding what this means for your center — and moving quickly to position yourself on the right side of it — may be one of the most important strategic decisions you make this year.

What the 2026 Rule Actually Does

At its core, the 2026 OPPS/ASC Final Rule advances site-neutral payment by narrowing the reimbursement gap between hospital outpatient departments (HOPDs) and ambulatory surgery centers. Here are the provisions that matter most:

•     CMS finalized a 2.6% payment increase for both ASCs and HOPDs — a positive update, but one that masks the more significant structural shift underneath.
•     560 procedures were added to the ASC Covered Procedures List, including cardiology, spine, and vascular cases previously restricted to hospital settings.
•     285 primarily musculoskeletal procedures were removed from the Inpatient-Only list in the first phase of a three-year wind-down, with full elimination by 2029.
•     Drug administration services in certain off-campus provider-based hospital departments are now subject to site-neutral payment — paid at the physician fee schedule rate rather than the higher OPPS rate, which in some cases is roughly 40% less.

The net effect is a deliberate realignment of financial incentives toward lower-cost outpatient settings. CMS is signaling — and increasingly formalizing — that the same procedure should not command dramatically different reimbursement simply because of where it’s performed.

$290M  — estimated 2026 Medicare savings from site-neutral drug administration payment changes alone, per CMS projections.

The Opportunity Hidden Inside the Risk

For ASCs, particularly physician-owned and independent centers, site neutrality is primarily good news — with important caveats. When reimbursement gaps between HOPDs and ASCs narrow, procedures naturally migrate toward the more efficient, lower-cost setting. ASCs consistently outperform hospitals on patient satisfaction, scheduling speed, infection rates, and cost per case. Under a more level payment playing field, those advantages translate directly into competitive wins.

‘Site-neutral payments will significantly benefit ASCs at large by reducing reimbursement gaps with HOPDs, driving increased procedure volume to lower-cost, independent and physician-owned settings,’ Dr. J. Eric Haas, Chief Medical Officer of the American Academy of Value-Based Care, told Becker’s in early 2026.

The expansion of the ASC Covered Procedures List reinforces this opportunity. Cardiology and orthopedic-spine are two of the highest-acuity, highest-revenue service lines now eligible for ASC-based delivery. Centers with the infrastructure, staffing, and payer contracts to support these cases stand to capture meaningful volume that previously lived in hospital operating rooms.

The Competitive Reset Already Underway

Here is where the picture gets more complicated for independent centers: health systems have been watching this shift, too — and they’re moving. According to an October 2025 report from the Center for Connected Medicine at UPMC Enterprises and KLAS Research, health systems are actively investing in ASC networks as ‘enterprise infrastructure,’ targeting high-growth and underserved markets. The competitive landscape in 2026 will increasingly pit scaled ambulatory platforms against independent centers, with capital, data, and contracting leverage often deciding outcomes.

In other words: site neutrality may level the Medicare reimbursement playing field, but it simultaneously intensifies the competitive battle for cases, physicians, and contracts. An ASC that doesn’t adapt its contracting strategy, service line mix, and operational capabilities to this new environment may find that the procedure migration flows toward affiliated centers rather than independent ones.

560  — new procedures added to the ASC Covered Procedures List for 2026. Centers without updated payer contracts and billing infrastructure for these codes are leaving revenue on the table from day one.

What ASC Leaders Need to Do Now

Review your payer contracts. Every contract with a site-of-service clause needs to be examined in light of the 2026 rule changes. Your negotiated rates for newly eligible procedures — cardiology, spine, vascular — may not reflect the current Medicare benchmark. If you haven’t renegotiated for new CPL additions, you may be billing at disadvantageous rates.

Audit your procedure mix for opportunity. With 560 new procedures eligible in the ASC setting, there are likely cases your center’s physicians perform in hospital ORs that could migrate to your facility — at lower cost, better access, and potentially better margin. This analysis requires both clinical and financial input, but it should be on your strategic agenda now.

Get ahead of the payer coverage lag. CMS eligibility is immediate. Commercial payer approval timelines are not. Major insurers may take 60 to 180 days to update coverage determinations for newly eligible procedures. Billing without payer-specific verification during that window is a systematic denial risk.

Build your quality data infrastructure. In an era of site neutrality, the ASC’s strongest negotiating asset with payers isn’t rate — it’s outcome data. Centers that can demonstrate superior outcomes, lower complication rates, and patient satisfaction scores have leverage in contract negotiations that will only grow as the payment environment evolves.

Site neutrality is neither a windfall nor a crisis for well-managed ASCs. It is a strategic reset — and the centers that understand its implications clearly and act decisively are the ones that will consolidate market share in 2026 and beyond.